Simplify Eylea Prior Authorization with Klivira

Klivira automates Eylea prior authorization, transforming a complex, manual process into a streamlined workflow for your ophthalmology or retina practice. Our platform is designed to expedite approvals for aflibercept, ensuring timely patient access to critical anti-VEGF therapies.

Managing Eylea (aflibercept) prior authorizations presents significant administrative burdens, impacting clinic efficiency and revenue cycles. The specific clinical criteria, frequent re-authorizations, and integration with buy-and-bill processes demand a robust, automated solution to minimize delays and reduce staff burnout.

The Challenges of Eylea Prior Authorization

Eylea (aflibercept), a critical anti-VEGF therapy, often requires meticulous prior authorization due to its high cost and specific indications like wet AMD, diabetic macular edema, and retinal vein occlusion. Manual processes for these specialty medications are prone to errors, leading to delays in treatment initiation and increased administrative overhead for your staff.

Key Indications for Eylea (Aflibercept)

  • Wet Age-related Macular Degeneration (AMD)
  • Diabetic Macular Edema (DME)
  • Macular Edema following Retinal Vein Occlusion (RVO)

Klivira's Intelligent Automation for Eylea

Klivira addresses the complexities of Eylea prior authorization by integrating directly into your existing EMR and automating the submission and tracking process. Our platform leverages intelligent rules engines to ensure all necessary clinical documentation is gathered and submitted accurately, aligning with payer-specific requirements for aflibercept.

How Klivira Streamlines Eylea PA Workflows

  • Automated data extraction from EMRs via SMART on FHIR for X12 278 submissions.
  • Real-time eligibility and benefit verification for aflibercept.
  • Proactive identification of payer-specific clinical criteria for Eylea.
  • Automated submission to payer portals and ePA channels (e.g., NCPDP SCRIPT, Da Vinci PAS).
  • Centralized dashboard for tracking Eylea PA status and appeals.

Enhancing Revenue Cycle Management for Buy-and-Bill Medications

For buy-and-bill drugs like Eylea, efficient prior authorization is directly linked to financial health. Klivira helps mitigate the financial risks associated with specialty medications by accelerating approval times and reducing denial rates, thereby improving cash flow and reducing write-offs for your practice.

Seamless Integration with Your Existing Infrastructure

Klivira is engineered for interoperability, integrating with leading EMR systems to create a cohesive workflow for Eylea prior authorizations. This reduces the need for manual data entry, minimizes disruptions to your clinical operations, and ensures that patient data (ePHI) is handled securely and efficiently.

Frequently asked questions

How does Klivira handle the buy-and-bill component for Eylea prior authorizations?

Klivira integrates PA automation with your existing financial systems, allowing for seamless coordination of benefits, eligibility checks, and authorization tracking alongside your buy-and-bill inventory and billing processes. This ensures financial readiness prior to drug administration, reducing claim denials.

Which EMR systems does Klivira integrate with for Eylea PA?

Klivira supports robust integrations with major EMR platforms via SMART on FHIR and other industry-standard APIs. This enables automated data exchange for Eylea (aflibercept) PA requests, minimizing manual data entry and ensuring data accuracy.

Can Klivira adapt to payer-specific requirements for Eylea (aflibercept)?

Yes, Klivira's platform includes a dynamic rules engine that is continuously updated with payer-specific clinical criteria and submission guidelines for Eylea. This ensures that each prior authorization request is tailored to the individual payer's requirements, increasing approval rates.

How does Klivira manage re-authorizations for ongoing Eylea treatments?

Klivira proactively tracks Eylea authorization expiration dates and initiates re-authorization processes automatically. The system alerts staff to upcoming deadlines and pre-populates re-authorization requests with relevant clinical updates, ensuring continuity of care without administrative gaps.

What security measures are in place for Eylea patient data (ePHI)?

Klivira adheres to stringent security protocols to protect ePHI, including robust encryption, access controls, and regular security audits. Our platform is designed with HIPAA compliance in mind, ensuring the confidentiality and integrity of all patient information handled during the Eylea prior authorization process.

Related coverage

Simplify prior authorization by payer

Simplify prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo